Skip to main
ACTU

ACTU Stock Forecast & Price Target

ACTU Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Actuate Therapeutics is a promising clinical stage biopharmaceutical company with a positive outlook due to their focus on developing targeted therapies for high-impact, difficult to treat cancers. Their lead candidate, elraglusib, has shown activity in preclinical pediatric models and has the potential for a short clinical development timeline with regulatory alignment. Additionally, their diverse pipeline and potential eligibility for a Priority Review Voucher upon approval in orphan oncology indications make Actuate a strong investment opportunity.

Bears say

Actuate Therapeutics is currently facing significant financial challenges with no revenues and consistently reporting net losses, leading to a pessimistic outlook on its stock performance. Additionally, the company's cash reserves are not sufficient to fund future operations, putting it at risk of potential bankruptcy. Furthermore, while the development of oral elraglusib remains a potential value driver, it may not be sufficient to offset the company's financial struggles and risks associated with clinical, manufacturing, and regulatory factors.

ACTU has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Actuate Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Actuate Therapeutics Inc (ACTU) Forecast

Analysts have given ACTU a Strong Buy based on their latest research and market trends.

According to 2 analysts, ACTU has a Strong Buy consensus rating as of Aug 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Actuate Therapeutics Inc (ACTU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.